About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Breaking News:
Verrica announced the approval of YCANTHâ„¢ (cantharidin) topical solution 0.7%
Document Details
Form: 8-K
Filing Date: February 21, 2023
Document Date: February 21, 2023
Form Description: Report of unscheduled material events or corporate event
Filing Group:
Current Reports
Company: Verrica Pharmaceuticals
Filing Formats
View HTML
Download PDF
Download DOC
Download XLS
BREAKING NEWS:
Verrica announced the approval of YCANTH (cantharidin) topical solution
Learn More
Please see
Important Safety Informa
tion
and full
Prescribing Information